Insight

Insights,

What Clinical Information Does CMS Need for Drug Price Negotiations Under the IRA?

Insights,

| Ashis Kumar Das, PhD, MD, MPH - Director

Real-World Effectiveness vs Clinical Trial Efficacy in Medicare

Insights,

| Ashis Kumar Das, PhD, MD, MPH - Director

Why is Medicare Data Central to IRA Negotiations?

Insights,

| Tyler Seville, MPA - Senior Manager

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development

Insights,

ADVI Analysis: HRSA 340B Covered Entity Audits
ADVI Angle Vertical

Insights,

| Allison Schneider, MHA - Director

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

Insights,

| Charles Sewell - Senior Associate

ADVI Analysis: MACPAC October 2024 Meeting

Insights,

| Brenna Raines, MHA - Vice President

ADVI Instant: CMS Releases 2026 Notice of Benefit and Payment Parameters Proposed Rule

Insights,

| Allison Schneider, MHA - Director

ADVI Analysis: MedPAC October 2024 Meeting